Osmind

Osmind

Mental Health Care

San Francisco, CA 8,740 followers

The premier technology platform for breakthrough mental health treatment and research.

About us

Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists to advance new evidence-generating medicine that helps people living with moderate to severe mental health conditions. For more information, please visit osmind.org. We're hiring! Learn more at osmind.org/careers

Website
http://osmind.org/
Industry
Mental Health Care
Company size
51-200 employees
Headquarters
San Francisco, CA
Type
Privately Held
Founded
2020

Locations

Employees at Osmind

Updates

  • View organization page for Osmind, graphic

    8,740 followers

    We are excited to announce a landmark collaboration with the American Psychiatric Association (APA) to advance quality psychiatric care and accelerate research. "At Osmind, we emphasize the importance of clinicians participating in evidence-generating medicine to help shape the future of mental health care, especially as the psychiatric field begins to embrace new treatments and precision psychiatry,” says Carlene MacMillan, MD, Chief Medical Officer of Osmind. “Clinicians in private practice juggle many competing demands so it is crucial we make participation both easy and worthwhile to them." To make participation in evidence-generating medicine easier for busy private practitioners, we’re integrating APA's diagnostic and outcomes measures directly into the Osmind EHR. We're starting with the DSM-5-TR Self-Rated Level 1 Cross-Cutting Symptom Measure, which joins our library of 40+ measures, enabling clinicians to contribute to research at the point of care. We’ll also explore an integration between the Osmind EHR and PsychPRO so that clinicians using the Osmind EHR can participate effortlessly in the PsychPRO registry. "PsychPRO is the tool healthcare organizations need to guide their efforts to deliver quality mental health care and improve patient outcomes," says Nitin Gogtay, M.D., APA Chief of Research and Deputy Medical Director. "Our collaboration with Osmind will allow us to strengthen PsychPRO today, and long-term offers promise to broaden the scope of our impact on psychiatry and on the patients we serve.” We are delighted to work with the APA, and proud to enable independent practices to contribute to the evolution of the field and elevate their own evidence-based practices. https://lnkd.in/g4RU7Ftt

    Osmind Announces Collaboration with the American Psychiatric Association | Osmind

    Osmind Announces Collaboration with the American Psychiatric Association | Osmind

    osmind.org

  • Osmind reposted this

    View profile for L. Alison McInnes  MD, MS, graphic

    Vice President of Scientific Affairs at Osmind

    It was so much fun to revisit the dawning of the golden era of psychiatry in the aughts. There had been no antidepressant therapies with a novel mechanism of action for over 60 years till TMS and ketamine emerged. David was an enthusiastic early adopter. These therapies have encouraged advances in neurostimulation and a renewed interest in developing medications for psychiatric disorders. David is a passionate advocate for insurance coverage for ketamine and for using ketamine for PTSD in underserved populations. Enjoy! David Feifel, MD, PhDOsmind

    View organization page for Osmind, graphic

    8,740 followers

    What do quantum physics and breakthrough psychiatric treatments have in common? Enter the golden era of psychiatry with David Feifel, MD, PhD. In our latest Psychiatry Tomorrow episode, Dr. Feifel shares how following his curiosity led him to surprising places: breakthrough treatments in a cancer center, academia at UCSD, private practice at Kadima Neuropsychiatry Institute, and abroad in Rwanda. You'll learn: -How Dr. Feifel’s curiosity with quantum physics sparked an unconventional path in psychiatry -How a cancer center unlocked an epiphany about set and setting -How combining cutting-edge therapies changes outcomes for treatment-resistant patients -The complex battle for insurance coverage of breakthrough treatments -Expanding innovative psychiatric care globally - from San Diego to Rwanda Ready to explore the future of psychiatry? 🎧 Read or listen to the interview with the link below. Or, search for "Psychiatry Tomorrow" on your favorite podcast app. https://lnkd.in/dVEubgx3

    Entering Psychiatry's Golden Era with Dr. David Feifel, MD, PhD | Osmind

    Entering Psychiatry's Golden Era with Dr. David Feifel, MD, PhD | Osmind

    osmind.org

  • View organization page for Osmind, graphic

    8,740 followers

    What do quantum physics and breakthrough psychiatric treatments have in common? Enter the golden era of psychiatry with David Feifel, MD, PhD. In our latest Psychiatry Tomorrow episode, Dr. Feifel shares how following his curiosity led him to surprising places: breakthrough treatments in a cancer center, academia at UCSD, private practice at Kadima Neuropsychiatry Institute, and abroad in Rwanda. You'll learn: -How Dr. Feifel’s curiosity with quantum physics sparked an unconventional path in psychiatry -How a cancer center unlocked an epiphany about set and setting -How combining cutting-edge therapies changes outcomes for treatment-resistant patients -The complex battle for insurance coverage of breakthrough treatments -Expanding innovative psychiatric care globally - from San Diego to Rwanda Ready to explore the future of psychiatry? 🎧 Read or listen to the interview with the link below. Or, search for "Psychiatry Tomorrow" on your favorite podcast app. https://lnkd.in/dVEubgx3

    Entering Psychiatry's Golden Era with Dr. David Feifel, MD, PhD | Osmind

    Entering Psychiatry's Golden Era with Dr. David Feifel, MD, PhD | Osmind

    osmind.org

  • View organization page for Osmind, graphic

    8,740 followers

    Congrats to Osmind Community Advisory Board members Tobias Marton MD, PhD and Richard Bermudes, M.D. on their important new study on TMS! The study showed that TMS was highly effective, but underutilized and restricted to more treatment-resistant patients, largely due to the restrictive payor criteria for TMS coverage at that time. This research highlights the urgent need to align payor criteria with current evidence. Doing so could expand TMS adoption and improve outcomes for depression patients. Kudos to Richard Bermudes, M.D., Tobias Marton MD, PhD, Mindful Health Solutions, and everyone fueling our mission to empower clinicians and researchers in bringing innovative mental health treatments to those who need them most. Together, we're paving the way for more accessible, effective mental health care.

    View profile for Tobias Marton MD, PhD, graphic

    Chief Medical Officer at Mindful Health Solutions

    Excited to publish this study in BMC Psychiatry with current and former MHS colleagues. Integrating and scaling TMS treatment to the general psychiatry population provides MHS the unique opportunity to analyze TMS utilization and outcomes alongside usual care such as standard pharmacotherapy. Our new study, based on analysis of our clinical utilization and outcomes patterns in 2020, shows that TMS was highly effective, but also underutilized and restricted to more treatment resistant patients, largely due to the restrictive payor criteria for TMS coverage at that time. While the payor landscape has improved in the last several years, our study shows the importance of aligning payor criteria for TMS with the current best evidence if we are to see wider adoption and earlier use of this life-saving technology in the treatment of depression.

  • View organization page for Osmind, graphic

    8,740 followers

    📊 The World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) is your quick functional assessment in psychiatry. Bookmark this quick reference guide and free score calculator: - History and development by WHO - 6 key domains of functioning assessed - Scoring and interpretation - Integration with DSM-5 for impairment assessment - Practical applications in clinical settings - Real-world case studies 🧮 Plus, try our free interactive WHODAS 2.0 score calculator for instant results and interpretations! Elevate your practice with evidence-based care: https://bit.ly/3Y66zFR

    WHODAS 2.0 Guide and Score Calculator | Osmind

    WHODAS 2.0 Guide and Score Calculator | Osmind

    osmind.org

  • View organization page for Osmind, graphic

    8,740 followers

    📊 The Generalized Anxiety Disorder-7 (GAD-7) is a cornerstone of anxiety assessment in psychiatry. It's essential to your Measurement-Based Care toolkit. Bookmark this quick reference guide: -Origins and development of the GAD-7 -Scoring system and interpretation guidelines -Psychometric strengths -Practical implementation in clinical practice -Real-world case studies showing its impact on treatment decisions -🧮 Plus, try our free interactive GAD-7 score calculator for instant results and interpretations! https://lnkd.in/dK-PYjwS

    GAD-7 Guide and Score Calculator | Osmind

    GAD-7 Guide and Score Calculator | Osmind

    osmind.org

  • View organization page for Osmind, graphic

    8,740 followers

    We're excited to announce Husseini Manji, M.D., F.R.C.P.C., a pioneering neuroscience leader who previously served as Global Head of Neuroscience at Janssen, has joined Osmind as a Strategic Advisor. Dr. Manji is renowned for bringing breakthrough, rapid-acting treatments to market, including esketamine (SPRAVATO®) for depression. His work has reconceptualized our understanding of severe neuropsychiatric disorders as genetically influenced disorders of synaptic and neural plasticity, leading to groundbreaking therapeutics. "I am excited to be a Strategic Advisor at Osmind, which is doing important, much-needed work. I truly believe that we are at an inflection point in our ability to markedly improve outcomes for our patients – both from an improved understanding of novel therapeutics, and our ability to move towards precision medicine." - Dr. Manji As the current Chair of the UK Government Mental Health Mission, Dr. Manji brings unparalleled expertise in developing treatments for neurologic, psychiatric, and pain-related disorders with high unmet needs. His insights will be crucial in advancing Osmind's research initiatives and supporting the development of innovative mental health treatments. Read the full announcement: https://lnkd.in/daVnnKcR

    Osmind Welcomes Dr. Husseini K. Manji, M.D., F.R.C.P.C., as a Strategic Advisor | Osmind

    Osmind Welcomes Dr. Husseini K. Manji, M.D., F.R.C.P.C., as a Strategic Advisor | Osmind

    osmind.org

  • Osmind reposted this

    I'm looking for someone to join me on our remote Care Team at Osmind. We have an opening for a Full Stack Software Engineer who wants to have a meaningful impact. Our vision is to build a platform so every person with mental health conditions can find a treatment that works for them. Osmind is the premier EHR for clinicians and researchers advancing new life-saving mental health treatments. If this role sounds interesting, please apply here: https://lnkd.in/gjf33FGw

    Osmind - Software Engineer

    Osmind - Software Engineer

    jobs.lever.co

  • View organization page for Osmind, graphic

    8,740 followers

    📊 The Patient Health Questionnaire-9 (PHQ-9) stands on the Mount Rushmore of psychiatric assessment tools. It's an essential part of any Measurement-Based Care starter kit. Save this quick reference guide: -History and development of the PHQ-9 -Scoring and interpretation methods -Psychometric properties -Practical applications in clinical settings -Case examples demonstrating its impact on treatment plans 🧮 Plus, instantly calculate and interpret PHQ-9 scores with our free interactive tool! Whether you're new to the PHQ-9 or looking to save time in your practice, this guide is your go-to resource for enhancing depression screening and monitoring. Dive in: https://lnkd.in/dgP6aSiZ

    PHQ-9 Guide and Score Calculator | Osmind

    PHQ-9 Guide and Score Calculator | Osmind

    osmind.org

  • View organization page for Osmind, graphic

    8,740 followers

    🩺 The DSM-5-TR Level 1 Cross-Cutting Symptom Measure (DSM-XC) is the stethoscope of psychiatry – and it's time to put it to use in your practice. Developed by the American Psychiatric Association, the DSM-XC is a powerful tool that helps you assess mental health symptoms across 13 psychiatric domains, ensuring a comprehensive and accurate screening. 📊 Osmind has collaborated with the APA to integrate this game-changing measure directly into our EHR, making it incredibly easy to access and implement in your daily practice. 🤝 Don't miss this opportunity to evolve your diagnostic process and provide the best care for your patients. 🔗 Read the full guide on our blog and start using the DSM-XC in your practice today. #PrecisionPsychiatry #MeasurementBasedCare #DSM5 #Osmind

Similar pages

Browse jobs

Funding

Osmind 4 total rounds

Last Round

Series B

US$ 40.0M

See more info on crunchbase